Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Johnson & Johnson and Momenta Pharmaceuticals have filed a patent infringement lawsuit over a generic multiple sclerosis drug developed by India-based Natco, Gland Pharma and Mylan.
Most of Samsung’s investment will be in South Korea, and it expects to create 80,000 new jobs through 2026, or about 16,000 positions annually.
Concerns are mounting for people that have been given Pfizer’s Paxlovid treatment regimen after contracting COVID-19, only to become positive for the infection once again.
Monday, Moderna told a Delaware federal court that it was immune from patent-infringement charges over the COVID-19 vaccine because it supplied the vaccine for a U.S. government effort.
There are many reasons why you might want to negotiate your stock options. Read on to discover what stock options are and how to negotiate your stock options with your employer.
In the third and most recent FDA letter, Verrica noted that none of the issues were specific to VP-102 and how it is manufactured.
Private investors, governmental institutions and longtime life sciences investors provided funding to develop therapies for cancers, dermatological problems and acute ischemic strokes.
Janssen shared positive updates from ongoing trials on candidate therapies for Crohn’s disease and ulcerative colitis at Digestive Disease Week in San Diego, California.
Vanda has again taken legal action against the FDA over its supposed failure to grant tradipant Fast Track designation. In its complaint, Vanda is challenging the FDA’s decision to deny the designation.
This summer, BioSpace will release a series of reports looking at the current state of diversity and inclusion in the life sciences.
Ocugen introduced NeoCart, which is designed to repair full-thickness lesions of the knee cartilage in adults, as a Phase III cell therapy platform technology.
A blood test to diagnose Alzheimer’s disease launched in April by Quest Diagnostics has the potential to screen patients for risk years before symptoms appear.